Entera Bio director granted 22,815 shares

Malca Yonatan reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Malca Yonatan reported acquisition or exercise transactions in this Form 4 filing.

Entera Bio Ltd. reported that director Yonatan Malca received a grant of 22,815 Ordinary Shares on August 7, 2026. The award, priced at $0.0000 per share, was issued in lieu of cash fees for serving as director for the first and second quarters of 2026. Following this grant, Malca directly holds 100,231 Ordinary Shares. The Board approved the grant on August 5, 2026, subject to effectiveness of a Registration Statement on Form S-8, which occurred on August 7, 2026.

Insider Trade Summary

Grant/Award: 22,815 shares

Grant/Award 1 txn

Insider Malca Yonatan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares, par value NIS 0.0000769 per share F1	22,815	$0.00	$0.00

Holdings After Transaction: Ordinary Shares, par value NIS 0.0000769 per share — 100,231 shares (Direct)

Footnotes (1)

1. F1. The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

Key Figures

Shares granted: 22,815 Ordinary Shares Grant price per share: $0.0000 per share Shares held after grant: 100,231 Ordinary Shares +1 more

4 metrics

Shares granted 22,815 Ordinary Shares Equity grant to director Yonatan Malca on August 7, 2026 in lieu of cash fees

Grant price per share $0.0000 per share Reported price for the non-cash equity award to the director

Shares held after grant 100,231 Ordinary Shares Director Yonatan Malca’s direct holdings following the August 7, 2026 grant

Service period covered first and second quarters of 2026 Board service period for which the share grant replaced cash director fees

Key Terms

in lieu of the cash fees, Registration Statement on Form S-8, Ordinary Shares, par value

4 terms

in lieu of the cash fees financial

"awarded these shares to the Reporting Person in lieu of the cash fees"

Registration Statement on Form S-8 regulatory

"subject to the filing by the Company of a Registration Statement on Form S-8"

A registration statement on Form S-8 is the U.S. Securities and Exchange Commission filing companies use to register shares they intend to grant to employees, directors, consultants or benefit plans under stock compensation programs. It matters to investors because it signals potential issuance of new shares tied to pay and incentives, which can increase the total shares outstanding — like adding more slices to a pie — reducing each existing share’s ownership and potentially affecting earnings per share and stock value.

Ordinary Shares financial

"Ordinary Shares, par value NIS 0.0000769 per share"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

par value financial

"Ordinary Shares, par value NIS 0.0000769 per share"

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Entera Bio (ENTX) director Yonatan Malca report?

Director Yonatan Malca reported receiving a grant of 22,815 Ordinary Shares of Entera Bio Ltd. on August 7, 2026. This non-cash award compensated him for serving as a director for the first and second quarters of 2026 and increased his direct holdings.

How many Entera Bio (ENTX) shares does Yonatan Malca hold after this grant?

After the grant, Yonatan Malca directly holds 100,231 Ordinary Shares of Entera Bio Ltd. This total reflects the addition of 22,815 shares awarded in lieu of cash director fees for the first half of 2026.

What was the price per share for the Entera Bio (ENTX) stock granted to Malca?

The shares granted to Yonatan Malca were reported at a price of $0.0000 per share. This reflects a compensatory equity award rather than a market purchase, provided instead of cash fees for his Board service in early 2026.

What period of service did the Entera Bio (ENTX) share grant to Malca cover?

The grant to Yonatan Malca covered director fees for the first and second quarters of 2026. Instead of receiving those fees in cash, he was awarded 22,815 Ordinary Shares as approved by Entera Bio’s Board of Directors.

Were conditions attached to the Entera Bio (ENTX) share grant to director Malca?

Yes. The share grant to Yonatan Malca was approved on August 5, 2026, subject to Entera Bio filing a Registration Statement on Form S-8 for the shares, which the company filed on August 7, 2026 before the grant became effective.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/07/2026 - 04:23 PM Accepted by SEC EDGAR 08/07/2026 - 04:22 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malca Yonatan

(Last) (First) (Middle)

KIRYAT HADASSAH

MINRAV BUILDING, FIFTH FLOOR

(Street)

JERUSALEM 9112002

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ ENTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value NIS 0.0000769 per share	08/07/2026		A(1)		22,815	A	$0	100,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Person in lieu of the cash fees the Reporting Person was entitled to for services rendered as a director of the Company for the first quarter and second quarter of 2026. This grant of shares was approved by the Board on August 5, 2026, subject to the filing by the Company of a Registration Statement on Form S-8 registering the shares, which occurred on August 7, 2026.

	/s/ Dana Yaacov-Garbeli, Attorney-in-Fact	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)